Boosting the Brain's Brakes to Beat Memory Loss
Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”
NJTV News
Vice President of Research and Development Sharon Rosenzweig-Lipson, PhD, was interviewed by NJTV News during the 17th International Conference on Alzheimer’s Drug Discovery, sponsored by the Alzheimer’s Drug Discovery Foundation.
Pine Journal
Promising early research by John Hopkins University and startup drug company AgeneBio successfully showed low dose treatment of AGB101 to lab animals, like rats, resulted in calmed over-activity in the brain and improved memory performance in subjects experiencing memory loss…
The Daily Record
Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development. Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab…
ALZFORUM
n the last session of CTAD, Michela Gallagher of Johns Hopkins University, Baltimore, fired up a tired audience with news that a proprietary low-dose formulation of the atypical antiepileptic drug levetiracetam, called AGB101, was set to start a Phase 3…
Johns Hopkins University Arts & Sciences Magazine
Could decelerating an overactive hippocampus halt Alzheimer’s disease in its tracks? Neuroscientist Michela Gallagher and her colleagues across the university aim to find out.
Bend Bulletin
What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…
Medical Xpress
What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…
Lawton Constitution
What could be one of the first treatments to delay or prevent Alzheimer’s disease received a big boost from the National Institute on Aging, which is putting up $7.5 million to help fund the next round of trials for the…
Imperial Valley News
Johns Hopkins University researchers have received an estimated $7.5 million National Institutes of Health grant to clinically test what would be the first treatment to prevent or delay the onset of Alzheimer’s dementia.
